Enveric Biosciences, INC 8-K filings

Enveric Biosciences has entered into an agreement to out-license its EB-002 drug candidate to MycoMedica Life Sciences, potentially earning up to $62 million in milestone payments and tiered royalties.

Enveric Biosciences has released an investor presentation on its website, which may be used in future communications with various stakeholders.

Enveric Biosciences has prioritized EB-003 as its lead development candidate and reported a net loss of $1.7 million for the second quarter of 2024.

Enveric Biosciences has granted Aries Science & Technology an exclusive license to develop and market its patented radiation dermatitis topical product.

Enveric Biosciences held its 2024 Annual Meeting of Stockholders, where shareholders voted on the election of directors, executive compensation, and the ratification of the company's auditor.

Enveric Biosciences has received notification from Nasdaq that it has regained compliance with the minimum stockholders' equity requirement for continued listing.

Enveric Biosciences has received a notification from Nasdaq regarding its failure to maintain the minimum bid price of $1.00 per share for continued listing.

Enveric Biosciences announced its first quarter 2024 financial results, highlighted by the discovery of seven novel drug candidate classes and the execution of non-binding term sheets potentially worth $410 million in milestone payments.

Enveric Biosciences issued 458,000 shares of common stock to institutional investors in exchange for a waiver of a variable rate transaction limitation, enabling the company to utilize its existing equity line of credit.

Enveric Biosciences has scheduled its 2024 Annual Meeting of Stockholders for May 28, 2024, and set an April 8, 2024 deadline for shareholder proposals.

Enveric Biosciences reported its 2023 financial results and provided a corporate update, emphasizing the selection of EB-003 as its lead drug candidate for mental health disorders.

Enveric Biosciences has signed two non-binding term sheets to out-license new chemical entities for joint disease treatments, potentially earning up to $82 million in milestone payments and royalties.

Enveric Biosciences has entered into agreements to issue 228,690 shares of common stock to institutional investors in exchange for a waiver of a variable rate transaction limitation, allowing the company to utilize its at-the-market offering facility.

Enveric Biosciences has signed three non-binding term sheets to out-license three classes of compounds, potentially earning up to $200 million in milestone payments and royalties.

Enveric Biosciences announced the discovery of a library of preclinical compounds across seven distinct molecule classes targeting mental health disorders, offering potential licensing opportunities.

Enveric Biosciences has received an extension from Nasdaq to meet the minimum stockholders' equity requirement by May 20, 2024, to avoid potential delisting.